POZEN Inc. (POZN) Updates on Royalty Position Following Pernix (PTX), Glaxo (GSK) Treximet Deal
- Tech mega-caps knock 1% off Nasdaq; banks lift Dow
- EV Company Polestar To Go Public Via $20 Billion SPAC Deal
- Amazon (AMZN) Price Target Lowered at Morgan Stanley Amid Rising Logistics Workforce Costs, Analyst Expects Stock to be Range Bound in Near Term
- Brent oil nears $80 a barrel on tight supply
- Some Apple (AAPL) and Tesla (TSLA) Suppliers Suspend Production in China For a Few Days
On May 13, 2014, POZEN Inc. (Nasdaq: POZN), Glaxo Group Limited, d/b/a GlaxoSmithKline (NYSE: GSK), CPPIB Credit Investments Inc. (“CII”) and Pernix Therapeutics Holdings, Inc. (Nasdaq: PTX), entered into certain agreements in connection with GSK’s divestiture of all of its rights, title and interest to develop, commercialize and sell Treximet (sumatriptan/naproxen sodium) in the U.S. (the “Divestiture”) to Pernix. In November 2011, POZEN entered into a Purchase and Sale Agreement with CII, pursuant to which it sold its right to receive future royalty payments arising from U.S. sales of MT 400, including Treximet®, to CII. Under the Purchase and Sale Agreement, POZEN will receive a twenty percent (20%) interest in any royalties received by CII relating to the period commencing on April 1, 2018.
Upon the closing of the Divestiture, GSK will assign the Product Development and Commercialization Agreement executed as of June 11, 2003 between POZEN and GSK (the “Agreement”) to Pernix. Immediately following the consummation of the Divestiture, Amendment No. 1 to the Agreement (“Amendment No. 1”) between POZEN and Pernix will become effective. Amendment No. 1, among other things, amends the royalty provisions of the Agreement to provide for a guaranteed quarterly minimum royalty of $4 million for the calendar quarters commencing on January 1, 2015 and ending on March 31, 2018 and requires that Pernix continue certain of GSK’s ongoing development activities and to undertake certain new activities, for which POZEN will provide reasonable assistance. Amendment No. 1 also eliminates restrictions in the Agreement on POZEN’s right to develop and commercialize certain dosage forms of sumatriptan/naproxen combinations outside of the United States and permits POZEN to seek approval for these combinations on the basis of the approved U.S. New Drug Application.
Pernix has also granted POZEN a warrant to purchase 500,000 shares of Pernix common stock at an exercise price equal to the closing market price on May 13, 2014. The warrants, which will be registered by Pernix with the Securities and Exchange Commission, will be exercisable from the closing date of the Divestiture until February 28, 2018.
Lastly, POZEN, GSK, Pernix and CII have executed a letter agreement whereby POZEN expressly consented to the assignment by GSK and the assumption by Pernix of the Agreement.
Amendment No. 1 and the letter agreement will become effective and the warrants will become exercisable upon the closing of the Divestiture, which is subject to certain closing conditions, including receipt of regulatory approval and financing.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ATARA Biotherapeutics (ATRA) Announces EMA Grants Accelerated Assessment of tab-cel for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
- Kraton Corporation (KRA) to be Acquired by DL Chemical Co for $2.5B Cash or $46.5/sh
- Crinetics Pharmaceuticals (CRNX) to Unveil its Parathyroid Hormone Receptor Antagonist Program at ASBMR
Create E-mail Alert Related CategoriesCorporate News, FDA, Guidance, Mergers and Acquisitions
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!